SF3B1 inhibitors such as E7107 were discontinued following cases of irreversible vision loss, while H3B-8800, despite alleviating transfusion dependence in a subset of MDS patients, did not achieve clearly defined clinical responses. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.